What veterinary professionals need to know about in-house vaccine titering

In-house vaccine titering is gaining traction as a practical tool for companion animal practices, with dvm360 coverage pointing to a broader shift from viewing titers as a fringe alternative to seeing them as one more evidence-based option in preventive care. The key change is operational: point-of-care testing now gives general practices a faster way to assess protective antibody responses for select core viral diseases without sending every sample to an outside lab. (dvm360.com)

That shift builds on years of guideline development. AAHA’s 2022 canine vaccination resources say routine titer testing to determine whether dogs should be revaccinated at currently recommended intervals is not usually advised, except in cases such as prior adverse vaccine responses, suspected vaccine-related autoimmune disease, or when pet parents are resistant or hesitant about boosters. WSAVA’s 2024 vaccination guidelines also continue to recognize antibody testing as part of the modern vaccination conversation, particularly for core diseases where serology correlates with protection. (aaha.org)

The strongest evidence remains focused on a limited set of pathogens. dvm360’s reporting, drawing on guidance from vaccination experts including Richard Ford, DVM, notes that positive titers have a high correlation with protective immunity for canine distemper virus, canine parvovirus, canine adenovirus, and feline panleukopenia virus. By contrast, titers for many noncore vaccines, and even some other common feline viral targets, don’t offer the same clinical confidence. That distinction matters because it keeps practices from overselling what in-house titering can do. (dvm360.com)

The validation data behind newer point-of-care assays are one reason interest is growing. In a 2022 JAVMA study, investigators evaluated a point-of-care dot blot ELISA against reference-standard virus neutralization and hemagglutination inhibition assays for canine adenovirus, parvovirus, and distemper. The assay showed sensitivity from 96.03% to 96.75%, specificity from 87.50% to 94.33%, and overall accuracy from 93.43% to 95.91%. The authors concluded it was a reliable, rapid screening test for healthy dogs older than 20 weeks. A separate clinical assessment published in 2023 further examined point-of-care testing for protective vaccinal antibody titers to canine viral diseases, underscoring that this is an active area of applied diagnostics research. (pubmed.ncbi.nlm.nih.gov)

Industry and expert commentary has been relatively consistent: titers are useful when used precisely. In dvm360 coverage, Ford urged clinicians to think less in terms of “vaccination versus titer testing” and more in terms of using antibody testing to assess response to vaccination. Today’s Veterinary Practice has echoed that framing, describing core vaccine titer testing as well established in companion animal medicine while cautioning that negative titers don’t always mean a previously vaccinated adult is fully susceptible, because immune memory may persist even when circulating antibody declines. (dvm360.com)

Why it matters: For veterinary teams, in-house titering could help personalize care, reduce unnecessary boosters in selected patients, and improve conversations with vaccine-hesitant pet parents who might otherwise decline preventive care altogether. It may be especially useful for adult dogs with unknown histories, patients with prior vaccine reactions, or cases where documenting immunity could support shared decision-making. At the same time, the workflow benefit of getting a same-visit answer has to be balanced against the need for careful interpretation, staff training, and clear messaging that a positive rabies titer, for example, does not substitute for legal rabies vaccination requirements. (dvm360.com)

There’s also a business and operational angle. In-house testing can create a new preventive care touchpoint, but only if practices build protocols around when to recommend it, which species and diseases to include, how to document results, and when a negative result should trigger revaccination versus a broader clinical discussion. The evidence suggests the best fit is not blanket screening, but targeted use in cases where the result will change management or improve client compliance. That’s broadly aligned with AAHA’s position and with the more nuanced framing seen in continuing education and practice literature. (aaha.org)

What to watch: The next phase will likely center on adoption, not discovery: whether more general practices add point-of-care titering to wellness workflows, how vendors and educators position these assays, and whether future guideline updates sharpen recommendations on when in-house serology should complement, rather than replace, standard vaccination schedules. (aaha.org)